Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Cytek BioSciences Inc’s stock clocked out at $3.47, down -2.53% from its previous closing price of $3.56. In other words, the price has decreased by -$2.53 from its previous closing price. On the day, 1.01 million shares were traded.
Ratios:
To gain a deeper understanding of CTKB’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.13. For the most recent quarter (mrq), Quick Ratio is recorded 4.95 and its Current Ratio is at 5.62. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $9.Stephens initiated its Overweight rating on December 14, 2023, with a $9 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Stock Price History:
Over the past 52 weeks, CTKB has reached a high of $7.63, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 3.34%, while the 200-Day Moving Average is calculated to be -30.63%.
Shares Statistics:
A total of 127.60M shares are outstanding, with a floating share count of 114.67M. Insiders hold about 9.47% of the company’s shares, while institutions hold 60.95% stake in the company.
